中二病

沉金+背钻工艺 七彩虹iGame X870E白火神图赏 专为AMD X3D处理器打造_我的网站

A |     (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。    8月24日消息，七彩虹正式推出iGame X870E VULCAN W OC V14白火神主板。     主打圣白智械纯白外观，面向AMD平台超频发烧友，首发定价3999元，8月24日开启预售，9月1日正式开售。    这款主板是黑火神的升级版本，PCB升级沉金、背钻工艺，降低高频信号干扰，PCIe通道重新分配，显卡插槽可以保持满血，接插件也做加固，整体超频上限进一步提升。    供电采用18+2+2相110A DrMOS方案，可以充分释放AMD锐龙9 9950X3D2旗舰处理器全部性能。     内存超频是一大亮点，优化布线设计，搭配锐龙8000系列处理器最高可以跑到10600MHz，国产DDR5颗粒也可以稳定超频至9000MHz以上。    板载时钟发生器，支持CPU外频调节，IO挡板自带X3D一键超频实体按键，就算不懂复杂参数，普通玩家也能一键拉高处理器性能，X3D AI高帧模式也新增对锐龙9 9950X3D2的适配。    拓展配置方面，主板配备5个M.2固态接口，其中2路PCIe5.0 x4，3路PCIe4.0 x4，硬盘全部插满也不会占用显卡带宽。     双USB4 40Gbps全功能接口、5G有线网卡搭配Wi‑Fi7，外设扩展性拉满。显卡、M.2散热装甲、Wi‑Fi 天线全部支持快拆，简化装机步骤。    外观上全套圣白合金全覆盖装甲，加入智械视窗冰蓝灯带，右侧自带火神智屏，可以实时监控硬件状态，还能自定义画面内容，搭配一体式金属背板辅助散热。    配备双64MB BIOS，可保存两套不同超频配置，一键切换游戏和生产力场景。    对比同规格竞品，这款主板在同样18+2+2供电规格下，价格具备明显优势，适合追求纯白整机、玩AMD X3D处理器的硬件玩家。                                                                                                                                                                         

Current article:http://iyu0vej.dinggaxilianmaiyuejienianguai.shop/a675x/xb7.html

Published on:06:13:04